https://doi.org/10.55788/0a5e9025
The latest results of the phase 2b/3 PRISM trial (NCT03497975) were eagerly awaited, as currently approved pharmacologic therapies for prurigo nodularis are still lacking. The trial investigated nalbuphine, a dual κ-opioid receptor agonist/µ-opioid receptor antagonist as treatment for pruritus in prurigo nodularis [1]. Of note, abuse and addiction potential in activation of the κ-opioid receptor was found to be very low to non-existent. Included were 353 patients, randomised to receive either placebo or 162 mg of oral nalbuphine in an extended-release formulation, twice daily, after a 2-week titration.
The participants comprised a multi-ethnic group with a mean age between 56–60 years and a slight predominance for women. In both arms, baseline mean WI-NRS values of 8.6 and 8.7 stood for very severe itch. As for quality-of-life, the participants presented with mean scores of >80 out of 100 points in the Itchy-quality-of-life (ItchyQoL) score. “The majority of the population (60%) had 20–100 nodules which is a lot, 30% had over 100 nodules, and only 10% had up to 20 nodules,” Prof. Sonja Ständer (University Medical Centre of Münster, Germany) said.
PRISM met its primary endpoint with significantly more participants responding to nalbuphine with a ≥4-point reduction in their WI-NRS compared with placebo at week 14 (24.7% vs 13.9%; P=0.0157). The significant difference between the 2 responder curves of nalbuphine and placebo began at week 6 (P=0.0027) and continued thereafter. Similarly, the quality-of-life improved significantly from week 6 onwards. The study also looked at the amelioration of pruriginous lesions. “Here we can say that nalbuphine interrupts the itch-scratch cycle and that the lesions can heal,” Prof Ständer stated.
Safety results were consistent with nalbuphine’s known profile. In line with the nalbuphine versus placebo results, the incidence of ≥1 treatment-emergent adverse event differed between the initial 2-week titration period (66.1% vs 31.3%) and the following fixed-dose therapy (48.2% vs 44.9%). Most common were gastrointestinal disorders, dizziness, and headache. “The safety profile is of course the issue with this drug, but on the other hand we can easily manage them and it’s all in the mild and moderate range,” Prof. Ständer commented.
All in all, she was very optimistic about nalbuphine as a potential novel treatment in prurigo nodularis.
- Ständer S. Oral nalbuphine extended-release is effective in severe prurigo nodularis–associated pruritus: results from a phase 2b/3, double-blind, placebo-controlled study. 3K, EADV Congress 2022, Milan, Italy, 7–10 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy? Next Article
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis »
« Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy? Next Article
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding “health benefit” of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Long-term improvement in alopecia areata with ritlecitinib therapy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com